Intraday Info: MannKind Corporation (NASDAQ:MNKD) locked on 28/12/2016 at $0.691. It has average volume 5.52 million whilst it totals volume 5,833,175. The company has EPS -0.52 and according to analysts next quarter EPS and next year estimate EPS will -0.03 and -0.16 respectively. And it total income 205.30 million.
Ownership Summary: MannKind Corporation has total institutional ownership 20.25% while its total outstanding shares 478 millions that’s value of holdings $66 million.
Active Positions: In the latest year, MNKD 57 holders have raised its positions while it contains total 11,246,177 shares. And the strength of reduced positions holders and held positions holders are 45 and 59 respectively.
New and Sold Out Positions: In MNKD force of new positions holders 13 and it has total shares 5,470,968. And force of sold out positions holders 9 and it has 195,659 shares.
Comparison with Other Company: The Market Value of MNKD is $330,140 below from AbbVie Inc. market value which is $104M. Current Last Sale of MNKD is $0.6906 below from ABBV current last sale which is $62.27.
MannKind Corporation permitted product is AFREZZA, a fast-performing, inhaled insulin used to manipulate high blood sugar in adults with type 1 and type 2 diabetes. MannKind employer has license and partnership agreement with Sanofi-Aventis Deutschland GmbH for the improvement of AFREZZA. The corporation become based in 1991 and is founded in Valencia, California.